![]() 2020: Endo acquired BioSpecifics Technologies for more than $500 million Īfter facing lawsuits over its production of vaginal mesh implants, Endo shut down its production in 2016 to avoid further litigation It had set aside more than $2.6 billion to payments for such cases.2018-19: Endo announced and then terminated a deal to acquire Somerset Therapeutics.The FTC required divestments of assets to Rising Pharmaceuticals for the deal to go through. 2015: Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.This expanded Endo's portfolio to include 12 additional products, including a variery of testosterone preparations, and Xiaflex (a treatment for Peyronie's disease) In the same year they also acquired Dava Pharmaceuticals. In September 2014, Endo offered to buy Auxilium Pharmaceuticals and its portfolio in a then rejected offer, before acquiring the company the following month in a deal valued at $2.6 billion. However, Teva prevailed in this acquisition with a substantially higher bid. 2014: In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.they could afford to pay more to acquire U.S. In July 2015, The Wall Street Journal noted Endo was using Ireland's lower tax rate to acquire U.S.–based life sciences firms and relocate them to Ireland's tax regime (i.e. The acquisition was subsequently used via Canadian tax laws to execute a corporate tax inversion to Ireland. 2013: Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.2011: Endo acquired medical device manufacturer American Medical Systems for more than $2 billion.2010: Endo acquired generic manufacturer Qualitest Pharmaceuticals for $1.2 billion.The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel. ![]() 2009: Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.2006: Endo acquired RxKinetix, leading to a fall in profits.1999: Predecessor Endo Pharmaceuticals Holdings agreed to buy Algos Pharmaceutical Corporation, in a bid to gain additional products for the painkiller market.The United States Department of Justice has objected to the plans, claiming they violate bankruptcy law. On AugEndo International Plc filed for Chapter 11 bankruptcy protection after reaching a $6 billion deal with some of its creditors. In 2022, Endo's stock fell below $1 as the company faced restructuring of its $8 billion of debt. Through the 2014 acquisition of Paladin Labs and subsequent corporate restructuring, Endo International plc was formed. In 2012 shareholders voted to again change name to Endo Health Solutions, with Endo Pharmaceuticals becoming a segment of the business. Through the merger with Algos, it changed name again to Endo Pharmaceuticals Holdings Inc. Įndo Pharmaceuticals Holdings was created as a result of a $277 million management buyout of the division from DuPont Merck in 1997, led by Carol Ammon. Percodan), a focus which continued during its acquisition by DuPont in 1969 (e.g. The product line focused on medication for the treatment of pain (e.g. By 1935 it had changed its name to Endo Products. In 1920, Intravenous Products of America was incorporated as a privately owned pharmaceutical business operating in New York. See also: Corporation tax in the Republic of Ireland § Corporate tax inversions
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |